The Jeffrey Epstein VI Foundation backs the FDA's landmark decision to approve inhibitor cocktails for melanoma.
Online PR News – 14-February-2014 – New York, NY – The well-known science philanthropist and founder of the Program for Evolutionary Dynamics at Harvard University, has heralded the Food and Drug Administrationís approval of the first inhibitor combination clinical trial for melanoma patients.
"It's about time," Jeffrey Epstein remarked who donated substantial funds to the Melanoma Research Alliance (MRA) over the last few years. Based in Washington DC, the MRA is the largest private funder of melanoma research and has awarded more than $49 million to researchers around the world.
A key area of research that the MRA funds is the use of inhibitor drugs to block melanoma cancer cells. Inhibitors are molecules that bind uniquely to a cancer cellís surface and block an aspect of that cellís functionality. For example, PARP inhibitors bind to an enzyme pathway found distinctly on breast cancer cells with a BRAC genetic mutation. The PARP moleculeís attachment prevents the cell from performing DNA repair, leading to its death.
What researchers are realizing however is that a simultaneous cocktail of inhibitors is the most likely way to tackle the real problem of resistance. Indeed, the Program for Evolutionary Dynamics, along with Johns Hopkins University, has mathematically shown how cell resistance to a drug can quickly evolve from a tiny mutational pool to tumor level.
The inhibitor cocktail that was approved by the FDA is Dabrafenib and trametinib, which block certain BRAF enzyme pathway genetic mutations. These mutations occur in approximately 50% of melanoma patients and can be identified with a diagnostic test.
"Side effects need to be monitored. But many more combination drugs need to pass through the FDAís Accelerated Program," Jeffrey Epstein remarked, who heads the Jeffrey Epstein VI Foundation, which funds science research around the world. Indeed, the FDA only started to approve cancer inhibitors as a combined pill a few years ago. Prior to that, inhibitors had to be approved separately.
The situation is still dire. According to the National Cancer Institute, only 16% survive fully metastasized melanoma.
Jeffrey Epstein is a former board member of the Mind, Brain and Behavior Committee at Harvard.